Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients

Cystic fibrosis (CF) is a progressive genetic disease that often requires lung transplant as a life-extending treatment option. Highly effective CF transmembrane conductance regulator (CFTR) modulator treatments (HEMT) have substantially improved pulmonary function and health-related quality of life for people living with CF [1 –3]. Additional benefits of HEMT include improved gastrointestinal (GI) function, growth, pancreatic function, sinus symptoms, and other measures [4–8]. With these profound extrapulmonary clinical improvements, some lung transplant recipients with CF have been started on elexacaftor/tezacaftor/i vacaftor (ETI) in an effort to improve non-pulmonary manifestations of CF.

Source: Journal of Cystic Fibrosis - April 23, 2022 Category: Respiratory Medicine Authors: Kathleen J. Ramos, Jennifer S. Guimbellot, Maryam Valapour, Lauren E. Bartlett, Travis Hee Wai, Christopher H. Goss, Joseph M. Pilewski, Albert Faro, Joshua M. Diamond, CFLTC Study Group Tags: Original Article Source Type: research